The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma
Open accessAbstract
BACKGROUND: Papillary renal-cell carcinoma, which accounts for 15 to 20% of renal-cell carcinomas, is a heterogeneous disease that consists of various types of renal cancer, including tumors with indolent, multifocal presentation and solitary tumors with an aggressive, highly lethal phenotype. Little is known about the genetic basis of sporadic papillary renal-cell carcinoma, and no effective forms of therapy for advanced disease exist. METHODS: We performed comprehensive molecular characterization of 161 primary papillary renal-cell carcinomas, using whole-exome sequencing, copy-number analysis, messenger RNA and microRNA sequencing, DNA-methylation analysis, and proteomic analysis. RESULTS: Type 1 and type 2 papillary renal-cell carcinomas were shown to be different types of renal cancer characterized by specific genetic alterations, with type 2 further classified into three individual subgroups on the basis of molecular differences associated with patient survival. Type 1 tumors were associated with MET alterations, whereas type 2 tumors were characterized by CDKN2A silencing, SETD2 mutations, TFE3 fusions, and increased expression of the NRF2-antioxidant response element (ARE) pathway. A CpG island methylator phenotype (CIMP) was observed in a distinct subgroup of type 2 papillary renal-cell carcinomas that was characterized by poor survival and mutation of the gene encoding fumarate hydratase (FH). CONCLUSIONS: Type 1 and type 2 papillary renal-cell carcinomas were shown to be clinically and biologically distinct. Alterations in the MET pathway were associated with type 1, and activation of the NRF2-ARE pathway was associated with type 2; CDKN2A loss and CIMP in type 2 conveyed a poor prognosis. Furthermore, type 2 papillary renal-cell carcinoma consisted of at least three subtypes based on molecular and phenotypic features. (Funded by the National Institutes of Health.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“another possible mechanism by which D-2-HG drives tumorigenesis is through the promotion of genetic instability, predisposing cells to oncogenic transformation103.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [103]
In the citing paper
“Genomic studies have established that somatic mutations in IDH1 and IDH2 are perhaps the first genetic events to occur during tumorigenesis in human glioma and AML, and appear to initiate pathogenesis by a common mechanism103,115-117.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [103]
In the citing paper
“The most commonly occurring cancers thought to arise from mutant IDH1/2 (mIDH1/2) include glioma, cartilaginous tumours, AML, angioimmunoblastic T cell lymphoma (AITL) and intrahepatic cholangiocarcinoma (ICC).”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [103]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,239
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Self-citationComprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Hypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177
Comprehensive molecular characterization of clear cell renal cell carcinoma
The Cancer Genome Atlas Research Network (2013) · Nature · doi:10.1038/nature12222 · Cited by 3,485
Self-citationDiscovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
The Multiple Leiomyoma Consortium (2002) · Nature Genetics · doi:10.1038/ng849 · Cited by 1,635
Flagged first, then by citations
1 of the 42 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Delahunt B, 1997, Mod Pathol, 10, 537
- Schmidt LS, 1998, Cancer Res, 58, 1719
Cited by
Sorted by citations
Items 801–900 of 1,000
Xu, Y., Kong, D., Li, Z., Qian, L., Li, J., & Zou, C. (2021) · PLoS ONE · doi:10.1371/journal.pone.0254868 · Cited by 8
Cancel, M., Fromont, G., Blonz, C., Chevreau, C., Rioux-Leclercq, N. C., Laguerre, B., Oudard, S. M., Gross‐Goupil, M., Gravis, G., Goldwasser, F., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.08.046 · Cited by 8
Magers, M. J., Perrino, C. M., Cramer, H. M., & Wu, H. H. (2019) · Cancer Cytopathology · doi:10.1002/cncy.22146 · Cited by 8
Optimal Management of First-Line Advanced Renal Cell Carcinoma: Focus on Pembrolizumab
Singh, A., Singh, I., Singh, N., & Puzanov, I. J. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s215173 · Cited by 8
Author Correction: Pan-cancer image-based detection of clinically actionable genetic alterations
Kather, J. N., Heij, L. R., Grabsch, H. I., Loeffler, C. M. L., Echle, A., Muti, H. S., Krause, J., Niehues, J., Sommer, K. A. J., Bankhead, P., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00149-6 · Cited by 8
Cell type-specific translational regulation by human DUS enzymesPreprint
Yu, N. J., Dai, W. H., Li, A., He, M., & Kleiner, R. E. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.03.565399 · Cited by 8
Genotype Phenotype Correlation of Renal Tumors in the Cancer Genome Atlas Database
Albertson, D. J., Barry, M., Liu, T., Mahlow, J., & Sirohi, D. (2024) · International Journal of Surgical Pathology · doi:10.1177/10668969241260236 · Cited by 7
Translational utility of a hierarchical classification strategy in biomolecular data analytics
Galea, D., Inglese, P., Cammack, L., Strittmatter, N., Rebec, M., Mirnezami, R., Laponogov, I., Kinross, J. K., Nicholson, J. K., Takáts, Z., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-14092-7 · Cited by 7
Papillary Renal Cell Carcinoma: Evolving Classification by Combined Morphologic and Molecular Means
Przybycin, C. G. (2024) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000434 · Cited by 7
Gong, Y., Zhang, C., Li, H., Yu, X., Li, Y., Liu, Z., & He, R. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46030123 · Cited by 7
The Evolving Molecular Landscape and Actionable Alterations in Urologic Cancers
Antar, R. M., Fawaz, C., Gonzalez, D., Xu, V. E., Drouaud, A., Krastein, J., Pio, F., Murdock, A., Youssef, K., Sobol, S. M., et al. (2024) · Current Oncology · doi:10.3390/curroncol31110511 · Cited by 7
Yan, M., Wang, R., Guan, W., Jiang, R., Wang, K., Liu, Y., & Wang, L. (2024) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-024-03968-5 · Cited by 7
Bigot, P., Boissier, R., Khene, Z., Albiges, L. K., Bernhard, J., Corréas, J.-M., Vergie, S. D., Doumerc, N., Ferragu, M., Ingels, A., et al. (2024) · Progrès en Urologie - FMC · doi:10.1016/j.fpurol.2024.08.011 · Cited by 7
Zhang, Y., Chen, F., & Creighton, C. J. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01029-x · Cited by 7
Angulo, J. C., Lopez, J. I., & Ropero, S. (2016) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-016-0231-2 · Cited by 7
Rogala, J., Kojima, F., Alaghehbandan, R., Agaimy, A., Martínek, P., Ondič, O., Ulamec, M., Sperga, M., Michalová, K., Pivovarčíková, K., et al. (2019) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2019.151441 · Cited by 7
Salgia, N., Philip, E. J., Ziari, M., Yap, K., & Pal, S. K. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051508 · Cited by 7
Suh, J., Jeong, C. W., Choi, S., Ku, J. H., Kim, H. H., Kim, K., & Kwak, C. H. (2020) · BMC Urology · doi:10.1186/s12894-020-00687-2 · Cited by 7
Gopinath, A., Mubeen, A., Jamal, M., Mohammed, I., Gopireddy, D. R., & Baskovich, B. W. (2021) · International Journal of Surgical Pathology · doi:10.1177/1066896921998435 · Cited by 7
Marques-Magalhães, Â., Graça, I. C. R., Miranda‐Gonçalves, V., Henrique, R., Lopez, M., Arimondo, P. B., & Jerónimo, C. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111681 · Cited by 7
Schweizer, L., Thierfelder, F., Thomas, C., Soschinski, P., Kim, H., Jödicke, R., Woltering, N., Förster, A., Teichmann, D., Siewert, C., et al. (2021) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12741 · Cited by 7
Xiong, S., Zhu, W., Li, X., Yu, Y., Yang, K., Zhang, L., Mi, Y., Li, X., & Zhou, L. (2021) · Translational Andrology and Urology · doi:10.21037/tau-21-329 · Cited by 7
Ferlicot, S., Just, P., Compérat, É., Rouleau, É., Tissier, F., Vaessen, C., & Richard, S. (2021) · Diagnostic Pathology · doi:10.1186/s13000-021-01170-8 · Cited by 7
The prognostic impact of Claudin 6 in papillary renal cell carcinoma
Mikuteit, M., Zschäbitz, S., Stöhr, C., Herrmann, E., Polifka, I., Agaimy, A., Trojan, L., Ströbel, P., Becker, F. O., Wülfing, C., et al. (2022) · Pathology - Research and Practice · doi:10.1016/j.prp.2022.153802 · Cited by 7
Basile, G., Rosiello, G., Larcher, A., Fallara, G., Martini, A., Re, C., Cignoli, D., Tian, Z., Karakiewicz, P. I., Mottrie, A., et al. (2022) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2022.05.012 · Cited by 7
How New Developments Impact Diagnosis in Existing Renal Neoplasms
Akgül, M., & Williamson, S. R. (2022) · Surgical pathology clinics · doi:10.1016/j.path.2022.07.005 · Cited by 7
Genomic profiles of renal cell carcinoma in a small Chinese cohort
Tai, S., Xu, D., Yu, Z., Guan, Y., Yin, S., Xiao, J., Xue, S., & Liang, C. Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1095775 · Cited by 7
Renal Neoplasia Occurring in Patients With PTEN Hamartoma Tumor Syndrome
Kozman, D., Kao, C., Nguyen, J., Smith, S. C., Kehr, E. L., Tretiakova, M., Przybycin, C. G., Williamson, S. R., Argani, P., Eng, C., et al. (2023) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000002079 · Cited by 7
Castillo, V. F., Masoomian, M., Trpkov, K., Downes, M. R., Brimo, F., van der Kwast, T., Yousef, G. M., Zakhary, A., Rotondo, F., Saad, G., et al. (2023) · Histopathology · doi:10.1111/his.15042 · Cited by 7
Cytomorphology of papillary renal neoplasm with reverse polarity
Satturwar, S. P., & Parwani, A. V. (2023) · CytoJournal · doi:10.25259/cytojournal_9_2023 · Cited by 7
Learning to estimate sample-specific transcriptional networks for 7,000 tumors
Ellington, C. N., Lengerich, B. J., Watkins, T. B. K., Yang, J., Adduri, A., Mahbub, S., Xiao, H., Kellis, M., & Xing, E. P. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2411930122 · Cited by 7
Zhang, K., Lee, H., Wei, G., & Manninen, A. (2016) · Oncotarget · doi:10.18632/oncotarget.12390 · Cited by 7
Renal Cell Carcinoma in Renal Transplantation: The Case for Surveillance
Bennett, W. M., Simonich, E. L., Garre, A. M., McEvoy, K. M., Farinola, M. A., & Batiuk, T. D. (2017) · Transplantation Proceedings · doi:10.1016/j.transproceed.2017.06.031 · Cited by 7
Noguchi, G., Furuya, M., Okubo, Y., Nagashima, Y., Kato, I., Matsumoto, K., Tanaka, R. J., Hisasue, S., Yao, M., & Kishida, T. (2018) · International Journal of Urology · doi:10.1111/iju.13760 · Cited by 7
Zhu, X., Tan, J., Liang, Z., & Zhou, M. (2019) · Medicine · doi:10.1097/md.0000000000016672 · Cited by 7
A Systematic Review of Systemic Treatment Options for Advanced Non-Clear Cell Renal Cell Carcinoma
Osterman, C. K., & Rose, T. L. (2020) · Kidney Cancer · doi:10.3233/kca-190078 · Cited by 7
Chen, S., Zhang, N., Zhang, E., Wang, T., Jiang, L., Wang, X., & Zheng, J. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.616972 · Cited by 7
Imaging evaluation of hereditary renal tumors: a pictorial review
Tanaka, T., Kawashima, A., Marukawa, Y., Kitayama, T., Masaoka, Y., Kojima, K., Iguchi, T., Hiraki, T., & Kanazawa, S. (2021) · Japanese Journal of Radiology · doi:10.1007/s11604-021-01109-5 · Cited by 7
Key Renal Neoplasms With a Female Predominance
Baniak, N., Barletta, J. A., & Hirsch, M. S. (2021) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000301 · Cited by 7
Pan, J., Lei, X., & Mao, X. (2021) · PeerJ · doi:10.7717/peerj.11455 · Cited by 7
Maia, M. C., Adashek, J. J., Bergerot, P. G., Almeida, L., Santos, S., & Pal, S. K. (2017) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2017.11.011 · Cited by 7
Genomic Alterations of Renal Cell Carcinoma and Clinical Implications in the Chinese Population
Zhang, S., Wang, B., Zhang, F., Ye, J., Ge, L., & Ma, L. (2019) · Medical Science Monitor · doi:10.12659/msm.914493 · Cited by 7
Pathogenesis and Diagnosis of Genitourinary Cancer
Guo, C. C., Shen, S. S., & Ro, J. Y. (2021) · Cancers · doi:10.3390/cancers13020347 · Cited by 7
Nakanishi, S., & Inokuchi, J. (2025) · International Journal of Urology · doi:10.1111/iju.70144 · Cited by 6
Recent Advances in nccRCC Classification and Therapeutic Approaches
Wang, H., Chang, Y., Wang, K., & Liu, R. (2025) · Cells · doi:10.3390/cells14221781 · Cited by 7
McNamara, M. A., Zhang, T., Harrison, M. R., & George, D. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00079-7 · Cited by 7
Rad, N. K., Vahidyeganeh, M., Mohammadi, M., Shpichka, A. I., Timashev, P. S., Hossein‐Khannazer, N., & Vosough, M. (2022) · International Journal of Translational Medicine · doi:10.3390/ijtm2040042 · Cited by 6
Crooks, D. R., Cawthon, G. M., Fitzsimmons, C. M., Perez, M., Ricketts, C. J., Vocke, C. D., Yang, Y., Middelton, L. A., Nielsen, D., Schmidt, L. S., et al. (2023) · Human Molecular Genetics · doi:10.1093/hmg/ddad131 · Cited by 6
Ahn, B., Jeong, J., Lee, Y. I., Park, J.-M., Yoon, S. Y., Song, C., & Cho, Y. M. (2024) · Journal of Urologic Oncology · doi:10.22465/juo.244800440022 · Cited by 6
Cheng, G., Yu, Y., Wang, L., & Pan, Q. (2020) · Aging · doi:10.18632/aging.103091 · Cited by 6
Renal Cell Tumors: Molecular Findings Reshaping Clinico-pathological Practice
Tretiakova, M. (2020) · Archives of Medical Research · doi:10.1016/j.arcmed.2020.08.003 · Cited by 6
Prognostic and Therapeutic Potential of the OIP5 Network in Papillary Renal Cell Carcinoma
Chow, M. J., Gu, Y. J., He, L., Lin, X., Dong, Y., Mei, W., Kapoor, A., & Tang, D. (2021) · Cancers · doi:10.3390/cancers13174483 · Cited by 6
Wei, B., Yu, M., Yao, J., Jiang, M., An, J., Yang, J., Lin, J., Zhao, Y., & Zhu, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.657951 · Cited by 6
Angori, S., Banaei‐Esfahani, A., Mühlbauer, K., Bolck, H. A., Kahraman, A., Karakulak, T., Poyet, C., Feodoroff, M., Potdar, S., Kallioniemi, O., et al. (2023) · European Urology Focus · doi:10.1016/j.euf.2023.03.005 · Cited by 6
Wang, B., Li, M., & Li, R. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1169395 · Cited by 6
Murali, R., & Gopalakrishnan, A. V. (2023) · Medical Oncology · doi:10.1007/s12032-023-02225-0 · Cited by 7
Liu, C., Yuan, Z.-Y., Zhang, X.-X., Chang, J.-J., Yang, Y., Sun, S., Du, Y., & Zhan, H.-Q. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e23184 · Cited by 6
Guinard, E., Legendre, L., Kramkimel, N., Avril, M.-F., Chassaing, N., Cabaret, O., Guillaud-Bataille, M., & Mazereeuw‐Hautier, J. (2016) · Dermatology · doi:10.1159/000445430 · Cited by 6
Procházková, K., Mírka, H., Trávníček, I., Pitra, T., Kolár, J., ROUSAROVA, M., Hošek, P., Bajcurová, K., Ferda, J., Staehler, M. D., et al. (2018) · Urologia Internationalis · doi:10.1159/000492719 · Cited by 6
Delahunt, B., Srigley, J. R., Judge, M. J., Amin, M. B., Billis, A., Camparo, P., Fleming, S., Griffiths, D. J., Antonio Lopez-beltran, B., Martignoni, G., et al. (2019) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2019-205959 · Cited by 6
Sharma, A. E., Parilla, M., Wanjari, P., Segal, J. P., & Antic, T. (2020) · International Journal of Surgical Pathology · doi:10.1177/1066896920956272 · Cited by 6
Metastatic nonclear renal cell carcinoma current review in evolving treatment strategies
Suárez, C., Mejia, N. M. D., Morales‐Barrera, R., González, M., Mateo, J., & Carles, J. (2021) · Current Opinion in Urology · doi:10.1097/mou.0000000000000869 · Cited by 6
A 25 year perspective on advances in the pathologic assessment and diagnosis of urologic cancers
Hansel, D. E. (2021) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2021.05.016 · Cited by 6
Funasaki, S., Mehanna, S., Ma, W., Nishizawa, H., Kamikubo, Y., Sugiyama, H., Ikeda, S., Motoshima, T., Hasumi, H., Linehan, W. M., et al. (2022) · Cancer Science · doi:10.1111/cas.15364 · Cited by 6
Grimaldi, A., Affinito, O., Salvatore, M., & Franzese, M. (2022) · Diagnostics · doi:10.3390/diagnostics12102452 · Cited by 6
Zhang, X., Liu, X., Xiong, R., & An, H. (2022) · Aging · doi:10.18632/aging.204383 · Cited by 6
de Joode, K., van de Geer, W. S., van Leenders, G. J. L. H., Hamberg, P., Westgeest, H. M., Beeker, A., Oosting, S. F., van Rooijen, J. M., Beerepoot, L. V., Labots, M., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-37764-z · Cited by 6
Targeted Delivery of Therapeutics to Urological Cancer Stem Cells
Liu, Q., Gu, J. H., Zhang, E. X., He, L., & Yuan, Z. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200403131514 · Cited by 6
Jikuya, R., Fukagawa, A., Ito, D., Ishihara, H., Takemura, K. N., Kashima, S., Kato, T., & Urabe, F. (2025) · International Journal of Urology · doi:10.1111/iju.70091 · Cited by 5
Du, Y., Sun, H., Shi, Z., Sui, X., Liu, B., Zheng, Z., Liu, Y., Xuan, Z., Zhong, M., Fu, M., et al. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01333-8 · Cited by 5
Gao, F., Gu, D., Zhang, H., Shi, C., Du, F., Zheng, B. J., Wu, H., & Zhao, Y. (2024) · BMC Medical Genomics · doi:10.1186/s12920-024-01957-w · Cited by 5
Toyoda, S., Fukuokaya, W., Mori, K., Kawada, T., Katayama, S., Nishimura, S., Maenosono, R., Tsujino, T., Adachi, T., Hirasawa, Y., et al. (2024) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyae108 · Cited by 5
APOBEC 3 C ‐mediated NF ‐κ B activation enhances clear cell renal cell carcinoma progression
Hase, N., Misiak, D., Taubert, H., Hüttelmaier, S., Gekle, M., & Köhn, M. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13721 · Cited by 5
Pezzicoli, G., Musci, V., Ciciriello, F., Salonne, F., Cafforio, P., Lionetti, N., Ragno, A., & Rizzo, M. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241298500 · Cited by 5
Recent progress in non-clear cell renal cell carcinoma: biology and therapeutic strategies
Yildirim, A., Moses, M. W., Gerke, M. B., Jani, Y. C., Thompson, J. C., Akova, U., & Bilen, M. A. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251345722 · Cited by 5
Liu, G., Zhu, Z., Xing, Y., Meng, H., Shinwari, K., Xiao, N., & Liu, G. (2025) · Hereditas · doi:10.1186/s41065-025-00487-4 · Cited by 5
A densely connected framework for cancer subtype classification
Li, Y., Zheng, D., Sun, K., Qin, C., Duan, Y., Zhou, Q., Yin, Y., Kan, H., & Hu, J. (2025) · BMC Bioinformatics · doi:10.1186/s12859-025-06230-0 · Cited by 5
Vries-Brilland, M. D., Hamilou, Z., Ghosh, S., Heng, D. Y. C., Wood, L. A., Basappa, N. S., Kollmannsberger, C., Graham, J., Bhindi, B., Finelli, A., et al. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf240 · Cited by 5
Alruwaii, Z. I., Williamson, S. R., Liang Cheng, C., & Al‐Obaidy, K. I. (2025) · Histopathology · doi:10.1111/his.70008 · Cited by 5
Personalisierte Medizin bei Nierenzelltumoren
Junker, K., & Zeuschner, P. (2019) · Aktuelle Urologie · doi:10.1055/a-0895-9201 · Cited by 5
Ofori, E. O., Alhassan, B. B. A., Ayabilah, E. A., Maison, P. O. M., Asante-Asamani, A., Atawura, H., Rahman, G. A., Akakpo, P. K., Imbeah, E. G., & Ofori, P. W. (2021) · African Journal of Urology · doi:10.1186/s12301-020-00103-z · Cited by 5
Wagner, H. E., Kenk, M., Fraser, M. E., Berlín, A., & Fleshner, N. E. (2021) · European Urology Focus · doi:10.1016/j.euf.2021.06.002 · Cited by 5
Origins and Timing of Emerging Lesions in Advanced Renal Cell Carcinoma
Wallace, A., Porten, S. P., Lo, A. A., Oreper, D., Lounsbury, N., Havnar, C., Pechuan-Jorge, X., Zill, O. A., & Meng, M. V. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0590 · Cited by 5
Donskov, F. N., Pinto, C. A., Predoiu, R. A., Fox, C., Georgsen, J. B., Skaarup, K., Burcu, M., Perini, R. F., & Steiniche, T. (2022) · Acta Oncologica · doi:10.1080/0284186x.2022.2119100 · Cited by 5
Identification of prognostic and therapeutic biomarkers in type 2 papillary renal cell carcinoma
Wang, Y., Tian, X., Zhu, S., Xu, W., Anwaier, A., Su, J., Gan, H., Qu, Y., Zhao, J., Zhang, H., et al. (2023) · World Journal of Surgical Oncology · doi:10.1186/s12957-022-02836-3 · Cited by 5
Complex immunophenotypes: renal cell carcinoma with concurrent loss of SDHB/INI1 and FH/INI1
Usatii, M., Erickson, L. A., Cheville, J. C., & Gupta, S. (2023) · Human Pathology · doi:10.1016/j.humpath.2023.05.003 · Cited by 5
FH-mutant glioma displaying the epigenetic signature of IDH-mutant astrocytomas
Zschernack, V., Thomas, C., Schaub, C., Kristiansen, G., Waha, A., Goschzik, T., Herrlinger, U., & Pietsch, T. (2024) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlae064 · Cited by 5
Metastatic renal cell carcinoma with occult primary: a multicenter prospective cohort
Jacquin, N., Flippot, R., Masliah‐Planchon, J., Grisay, G., Brillet, R., Dupain, C., Kamal, M. T., Guillou, I., Gruel, N., Servant, N., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00648-0 · Cited by 5
2024 CUA-KCRNC Expert Report: Management of non-clear cell renal cell carcinoma
Graham, J., Ahmad, A. E., Basappa, N. S., Bernhard, J., Bhindi, B., Bossé, D., Breau, R. H., Canil, C. M., Castonguay, V., Finelli, A., et al. (2024) · Canadian Urological Association Journal · doi:10.5489/cuaj.9041 · Cited by 5
Dong, Y., Shayegan, B., Su, Y., Neira, S. V., & Tang, D. (2025) · BJC Reports · doi:10.1038/s44276-025-00128-3 · Cited by 6
Sanfrancesco, J. M., Eble, J. N., Grignon, D. J., Wang, M., Zhang, S., Sundaram, C. P., Idrees, M. T., Пили, Р., Kouba, E., & Liang Cheng, C. (2017) · Molecular Carcinogenesis · doi:10.1002/mc.22699 · Cited by 5
Naglieri, E., Asabella, A. N., Nappi, A. G., Carella, C., Ferrari, C., & Rubini, G. (2019) · Medicine · doi:10.1097/md.0000000000018093 · Cited by 5
Charakterisierung der unterschiedlichen Entitäten beim Nierenzellkarzinom
Rupp, N. J., & Moch, H. (2020) · Der Urologe · doi:10.1007/s00120-019-01108-5 · Cited by 5
Wei, J., Qian, Y., Tang, Y., Ge, X., Jiang, K., Fang, Y., Fu, D., Kong, X., Xiao, Q., & Ding, K. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s288663 · Cited by 5
Cui, K., Gong, L., Wang, K., Wang, Y., Huang, L., Liu, B., Li, Q., Zhang, Q., Fei, B., & Huang, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.888757 · Cited by 5
Importance of tumor subtypes in cancer imaging
Khader, A., Braschi‐Amirfarzan, M., McIntosh, L., Gosangi, B., Wortman, J. R., Wald, C., & Thomas, R. (2022) · European Journal of Radiology Open · doi:10.1016/j.ejro.2022.100433 · Cited by 5
Advanced Nanomaterials for the Diagnosis and Treatment of Renal Cell Carcinoma
Chen, G., Li, J., Mei, J., Su, W., Dai, H., Li, F., & Liu, P. (2022) · Advanced NanoBiomed Research · doi:10.1002/anbr.202200079 · Cited by 5
Renal cell carcinoma: what’s new in 2019
Evsyukova, О. I., & Matveev, V. В. (2019) · Cancer Urology · doi:10.17650/1726-9776-2019-15-4-120-125 · Cited by 5
Paraneoplastic encephalitis associated with renal cell carcinoma
Jang, Y., Kim, S., Chu, K., Lee, S. K., & Lee, S. (2021) · encephalitis · doi:10.47936/encephalitis.2021.00059 · Cited by 5
Genetics of Renal Cell Carcinoma
Ball, M. W., & Linehan, W. M. (2018) · Springer eBooks · doi:10.1007/978-3-319-92309-3_3 · Cited by 5
Metadata
- Authors
- The Cancer Genome Atlas Research Network
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- The Cancer Genome Atlas Research Network
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-01-14
- Volume
- 374
- Issue
- 2
- Pages
- 135-145
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4775252
- OpenAlex
- W2111867681
- Cited by
- 1,336
- References
- 42
- Citations by year
- 2026: 60 · 2025: 100 · 2024: 95 · 2023: 130 · 2022: 135 · 2021: 159 · 2020: 153 · 2019: 151 · 2018: 128 · 2017: 126 · 2016: 96
- FWCI
- 92.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (UL1TR000005)
- National Human Genome Research Institute (U54HG003067, U54HG003079, U54HG003273)
- National Cancer Institute (K24CA172355, U24CA143882, U24CA143843, U24CA143840, U24CA143858, U24CA144025, U24CA143866, U24CA199461, U24CA143883, U24CA143845, U24CA180951, U24CA143867, R01CA169172, U24CA143848, U24CA143799, U24CA143835, P30CA008748, P30CA015083, P30CA016672, P30CA016056, P30CA016086)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- papillary renal cell carcinoma, type 2 papillary renal cell carcinoma, MET alterations, SETD2 mutation, TFE3 fusion, Nrf2/ARE pathway, CpG island methylator phenotype, tumor subtypes, prognosis, molecular heterogeneity
- MeSH terms
- Carcinoma, Papillary, Humans, Kidney Neoplasms, Mutation, Phenotype, RNA, Messenger, RNA, Neoplasm, Signal Transduction, Sequence Analysis, RNA, CpG Islands, DNA Methylation, Proto-Oncogene Proteins c-met, MicroRNAs, NF-E2-Related Factor 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
